Metodologias de análise de bioequivalência entre varfarina de referência e genérica: comparativo entre agências reguladoras
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora - Campus Avançado de Governador Valadares
DOI
Abstract
As drug regulators are controlled by the production and marketing of drugs. For a quality
of a genetic medicine to be met, bioequivalence tests must be performed. These were the reference
results and the test of a not very significant series of bioavailability. Line limits are regulated by
regulators, as well as the conditions for testing to be performed. Warfarin, a narrow therapeutic index
(NTI) drug, should be more stringent to be considered bioequivalent, considering risks that may occur
to the patient, such as bleeding that can lead to death due to its narrow therapeutic window, which
makes it a BIT drug. ANVISA, the Brazilian regulatory manufacturer, determines bioequivalence
between 95% and 105% for NTI drugs; the US Food and Drug Administration (FDA) is more
permissive, with limits of 80% and 125%, but with the payment of statistics for a warfarin, inducing a7
new update. A European Medicines Agency (EMA) uses a similar analysis to the FDA, and
acceptance limits between 90% and 111.11% for NTI drugs. Some studies point to the FDA, and
others also point out tests that will be performed with a warfarin to assess its bioavailability, involving
in vitro tests and even pharmacogenetics.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

